Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


FDA’s Compounding Oversight: What Price Safety?

Executive Summary

As meningitis outbreak widens, FDA and members of Congress are calling for clarification of what jurisdiction the agency has over pharmacies, but agency officials are stopping short of asking for clear new authorities.


Related Content

FDA Panel Showdown Coming Over Epidural Steroid Injection Safety
Rx Response Planning Tweaks After Successful Efforts In Super Storm Sandy
CDER Compounding Oversight Challenge Forces Axelrad To Narrow Her Focus
Congress Expands Compounding Investigation To Trade Group
FDA Compounding Summit With States: Strategic Step Forward Or 50 More Cooks?
FDA Guidance Policy Could Be Hurt By Ruling On Animal Drug Compounding
Avastin-Related Eye Infections Could Bring FDA Pressure On Compounding Pharmacies
Compounded Drugs May Return To Supreme Court After 5th Circuit Backs FDAMA
Dusa Patent Suit Challenges Compounding Of Levulan
Supreme Court Reaffirms Least Restrictive Standard For Ad Controls


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts